MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
IOBT IO Biotech
- 0.771
- +0.011+1.43%
Close Dec 20 16:00 ET
- 0.750
- -0.021-2.70%
Post 20:01 ET
50.79MMarket Cap-0.60P/E (TTM)
0.781High0.750Low214.72KVolume0.750Open0.760Pre Close164.88KTurnover0.77%Turnover RatioLossP/E (Static)65.88MShares2.09852wk High0.70P/B21.47MFloat Cap0.66052wk Low--Dividend TTM27.84MShs Float17.880Historical High--Div YieldTTM4.12%Amplitude0.660Historical Low0.767Avg Price1Lot Size
About IO Biotech Company
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolIOBT
Company NameIO Biotech
Listing DateNov 5, 2021
Issue Price14.00
Founded2014
CEODr. Mai-Britt Zocca, PhD
MarketNASDAQ
Employees68
Fiscal Year Ends12-31
AddressOle Maal?es Vej 3
CityCopenhagen
ProvinceNorth Denmark
CountryDenmark
Zip Code2200
Phone45-70-70-29-80
Websitehttp://www.iobiotech.com
Company Executives
- Name
- Position
- Salary
- Dr. Mai-Britt Zocca, PhD
- Chief Executive Officer, President and Director
- 1.65M
- Dr. Qasim Ahmad, M.D.
- Chief Medical Officer
- 920.76K
- Amy Sullivan, M.B.A.
- Chief Financial Officer
- --
- Dr. Peter Hirth, PhD
- Chairman of the Board
- 145.75K
- Heidi Hunter
- Independent Director
- 112.61K
- David V. Smith, M.B.A.
- Independent Director
- 124.17K
- Kathleen Sereda Glaub, M.B.A.
- Independent Director
- 133.00K
- Dr. Helen Collins, M.D.
- Independent Director
- 52.48K
- Dr. Christian Elling, PhD
- Independent Director
- 114.14K
- Devin Whittemore Smith
- General Counsel
- 917.30K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.